Fragile X and Increased NT: A Prenatal Testing Case \| MDster                                                show = false, 1500)" role="region" aria-label="Connection status" aria-atomic="true" x-bind:aria-live="offline ? 'assertive' : 'polite'" x-bind:aria-hidden="(!show).toString()" class="offline-banner max-w-sm mx-auto px-4 py-3 text-sm font-bold text-center text-white rounded-full shadow-lg transition-all duration-500 ease-in-out" :class="{ 'hidden-state': !show, 'bg-error': offline, 'bg-success': !offline }"&gt;      You are offline 

     Back online! 

  [  MDster home ](/ "MDster home") 

  Specialities     [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Neurology ](https://mdster.com/speciality/neurology) [ Obstetrics &amp; Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) 

 [ Features ](https://mdster.com/features) [ SOE Examiner NEW ](https://mdster.com/soe-examiner) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) 

 Menu      

  Specialities     [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Neurology ](https://mdster.com/speciality/neurology) [ Obstetrics &amp; Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) 

 [ Features ](https://mdster.com/features) [ SOE Examiner NEW ](https://mdster.com/soe-examiner) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) 

 [     Login    ](https://mdster.com/auth/login) 

 1. [        Home  ](https://mdster.com)
2. [   Blog  ](https://mdster.com/blog)
3. [   Case Discussion  ](https://mdster.com/blog?category=case-discussion)
4. Fragile X Risk and Increased Nuchal Translucency: A Prenatal Case

  [ Case Discussion ](https://mdster.com/blog?category=case-discussion)  

 Fragile X Risk and Increased Nuchal Translucency: A Prenatal Case 
===================================================================

 How to counsel a patient when an FMR1 family history and an elevated NT call for different tests

  [     MDster Editorial Team ](https://mdster.com/about) ·      Oct 06, 2026  ·      7 min read  ·       188  

  [     Reviewed by Dr. Ali Ragab, MBBCH, MSc, MCAI ](https://mdster.com/medical-reviewers/dr-ali-ragab) [Editorial Policy](https://mdster.com/editorial-policy) \| [Corrections Policy](https://mdster.com/corrections) 

    [ Obstetrics &amp; Gynecology ](https://mdster.com/blog?tag=obstetrics-gynecology) [ Case Discussion ](https://mdster.com/blog?tag=case-discussion) [ Genetic Counseling ](https://mdster.com/blog?tag=genetic-counseling) [ Fragile X Syndrome ](https://mdster.com/blog?tag=fragile-x-syndrome) [ Prenatal Genetics ](https://mdster.com/blog?tag=prenatal-genetics) [ Nuchal Translucency ](https://mdster.com/blog?tag=nuchal-translucency)  

                                                          ![Fragile X Risk and Increased Nuchal Translucency: A Prenatal Case](https://mdster.com/storage/blog/images/fragile-x-risk-and-increased-nuchal-translucency-a-prenatal-case.png)  

    Share this article 

        Share this post 

 On this page

 1. [ Two Findings, Two Diagnostic Questions ](#two-findings-two-diagnostic-questions)
2. [ The brother’s phenotype suggests fragile X ](#the-brothers-phenotype-suggests-fragile-x)
3. [ The NT finding requires a separate workup ](#the-nt-finding-requires-a-separate-workup)
4. [ Screening Cannot Answer Every Question ](#screening-cannot-answer-every-question)
5. [ Match each test to its target ](#match-each-test-to-its-target)
6. [ The 80-Repeat Result Changes Counseling ](#the-80-repeat-result-changes-counseling)
7. [ Inheritance is not the same as expansion ](#inheritance-is-not-the-same-as-expansion)
8. [ Choosing a Diagnostic Procedure ](#choosing-a-diagnostic-procedure)
9. [ Earlier information versus a different tissue sample ](#earlier-information-versus-a-different-tissue-sample)
10. [ Document a decision, not just a signature ](#document-a-decision-not-just-a-signature)
11. [ Key Points for Board Exams ](#key-points-for-board-exams)
12. [ Frequently Asked Questions ](#blog-faqs)
13. [ References ](#references-heading)

 On this page

 1. [ Two Findings, Two Diagnostic Questions ](#two-findings-two-diagnostic-questions)
2. [ The brother’s phenotype suggests fragile X ](#the-brothers-phenotype-suggests-fragile-x)
3. [ The NT finding requires a separate workup ](#the-nt-finding-requires-a-separate-workup)
4. [ Screening Cannot Answer Every Question ](#screening-cannot-answer-every-question)
5. [ Match each test to its target ](#match-each-test-to-its-target)
6. [ The 80-Repeat Result Changes Counseling ](#the-80-repeat-result-changes-counseling)
7. [ Inheritance is not the same as expansion ](#inheritance-is-not-the-same-as-expansion)
8. [ Choosing a Diagnostic Procedure ](#choosing-a-diagnostic-procedure)
9. [ Earlier information versus a different tissue sample ](#earlier-information-versus-a-different-tissue-sample)
10. [ Document a decision, not just a signature ](#document-a-decision-not-just-a-signature)
11. [ Key Points for Board Exams ](#key-points-for-board-exams)
12. [ Frequently Asked Questions ](#blog-faqs)
13. [ References ](#references-heading)

A reassuring cell-free DNA result could still miss this patient’s central concern: whether her fetus inherited a fragile X full mutation. At 11 weeks, a 32-year-old primigravida reports a brother with severe intellectual disability, autism, prominent ears, and a prominent jaw. Her fetal crown-rump length (CRL) is 45 mm, and nuchal translucency (NT) measures 3.2 mm. She wants diagnostic certainty but fears pregnancy loss from an invasive procedure.

Two Findings, Two Diagnostic Questions
--------------------------------------

### The brother’s phenotype suggests fragile X

Fragile X syndrome is the leading consideration, not a diagnosis established by appearance. If available, obtain the brother’s genetic report; other inherited neurodevelopmental disorders and chromosomal conditions remain possible. Regardless, this family history warrants genetic counseling and targeted maternal *FMR1* CGG-repeat testing. [\[1\]](#cite-1 "Reference &#91;1&#93;")

*FMR1* disorders follow an X-linked inheritance pattern with markedly variable expression. A full mutation, usually more than 200 CGG repeats with abnormal methylation, reduces FMR1 expression; approximately 55–200 repeats constitute a premutation. Maternal transmission can expand a premutation into a full mutation, producing anticipation across generations. A father with a premutation transmits it to daughters, not sons, and paternal transmission does not ordinarily produce a full mutation. [\[1\]](#cite-1 "Reference &#91;1&#93;")

### The NT finding requires a separate workup

An NT of 3.2 mm at a CRL of 45 mm is increased; confirm measurement quality with an appropriately trained sonographer. Increased NT raises concern for aneuploidy, other genetic conditions, and structural abnormalities, particularly cardiac disease. It does **not** establish fragile X syndrome or explain the brother’s phenotype. [\[2\]](#cite-2 "Reference &#91;2&#93;")

The immediate differential therefore has two tracks:

- **Familial neurodevelopmental risk:** an *FMR1* expansion is plausible; the brother’s molecular diagnosis would sharpen interpretation.
- **Fetal increased-NT risk:** trisomy 21 and other chromosomal abnormalities require assessment, alongside later evaluation for structural anomalies.
- **Coincidence:** the family history and NT may reflect unrelated processes; do not force them into one diagnosis. [\[1\]](#cite-1 "Reference &#91;1&#93;")

For board examinations, the usual cellular origin of free trisomy 21 is maternal meiotic nondisjunction, most often in meiosis I. That mechanism is distinct from *FMR1* repeat expansion. [\[3\]](#cite-3 "Reference &#91;3&#93;")

Screening Cannot Answer Every Question
--------------------------------------

### Match each test to its target

Screening changes an estimated probability; diagnostic testing examines a sampled pregnancy for specified conditions. Maternal *FMR1* testing establishes her repeat status, but a positive result does not establish the fetus’s status. First-trimester combined screening and cell-free DNA (cfDNA) assess aneuploidy risk; neither substitutes for fetal *FMR1* repeat analysis. [\[4\]](#cite-4 "Reference &#91;4&#93;")

OptionUseful answerImportant limitMaternal *FMR1* testIs she a premutation or full-mutation carrier?Does not diagnose the fetuscfDNA or combined screeningWhat is the estimated risk of common aneuploidies?Does not diagnose trisomy 21 or fragile XCVS or amniocentesisDoes the fetal sample have a specified genetic finding?Only conditions requested and technically assessed are addressed

CfDNA is the most sensitive and specific screening option for common fetal aneuploidies, including trisomy 21, but even a low-risk result does not resolve an increased NT. A positive result requires counseling and an offer of diagnostic confirmation. After an enlarged NT, offer genetic counseling, diagnostic testing, and a detailed ultrasound evaluation rather than treating cfDNA as a definitive answer. [\[4\]](#cite-4 "Reference &#91;4&#93;")

The 80-Repeat Result Changes Counseling
---------------------------------------

### Inheritance is not the same as expansion

Suppose maternal testing identifies 80 CGG repeats on one *FMR1* allele. This is a **premutation**, not a maternal full-mutation diagnosis. Each pregnancy has a 50% chance of inheriting her expanded allele; whether an inherited premutation expands to a full mutation is a separate probability. Expansion risk depends on repeat length and AGG interruptions, so 80 repeats alone cannot support a precise fetal-risk estimate. [\[1\]](#cite-1 "Reference &#91;1&#93;")

A male fetus with a full mutation is generally expected to have intellectual disability. A female fetus with a full mutation has less predictable expression, influenced partly by X-inactivation; neither fetal sex nor repeat count reliably predicts an individual child’s developmental course. Offer targeted prenatal *FMR1* diagnosis and discuss the patient’s own future risk of fragile X-associated primary ovarian insufficiency and tremor/ataxia syndrome. [\[1\]](#cite-1 "Reference &#91;1&#93;")

Choosing a Diagnostic Procedure
-------------------------------

### Earlier information versus a different tissue sample

At 11 weeks, chorionic villus sampling (CVS) offers an earlier answer from placental tissue; amniocentesis is generally performed from 15 weeks and samples amniotic fluid. Either can provide material for targeted *FMR1* repeat analysis and chromosomal testing. Discuss chromosomal microarray with genetics and maternal–fetal medicine specialists in light of the increased NT; it does not replace the specific *FMR1* assay. [\[5\]](#cite-5 "Reference &#91;5&#93;")

- **If timing matters most:** offer CVS after confirming gestational age and arranging the requested laboratory analyses.
- **If placental findings are ambiguous:** discuss whether amniocentesis is needed for clarification. Confined placental mosaicism can complicate chromosomal interpretation; *FMR1* methylation assessment on CVS may also require follow-up. [\[1\]](#cite-1 "Reference &#91;1&#93;")
- **If avoiding an invasive procedure matters most:** noninvasive screening remains an option, provided she understands that it cannot establish fetal *FMR1* status or fully investigate increased NT. [\[4\]](#cite-4 "Reference &#91;4&#93;")

> **Clinical Pearl:** Order the fetal *FMR1* assay explicitly. A chromosomal microarray or a low-risk cfDNA result must not be mistaken for a fragile X diagnosis. [\[1\]](#cite-1 "Reference &#91;1&#93;")

### Document a decision, not just a signature

Before CVS or amniocentesis, use teach-back to document four elements: her understanding of what each requested assay can and cannot detect; benefits, uncertain findings, and procedural risks, including pregnancy loss; screening, later testing, and declining testing as alternatives; and a voluntary, non-directive choice. Avoid presenting a single miscarriage estimate as universally applicable: discuss the procedure-specific estimate and local operator experience. [\[6\]](#cite-6 "Reference &#91;6&#93;")

Arrange detailed fetal anatomy assessment at 18–22 weeks regardless of the genetic result. Further cardiac evaluation should reflect the confirmed NT measurement, subsequent imaging, and specialist assessment. [\[7\]](#cite-7 "Reference &#91;7&#93;")

Key Points for Board Exams
--------------------------

- An affected brother suggests fragile X, but his phenotype alone cannot confirm the familial mutation. [\[1\]](#cite-1 "Reference &#91;1&#93;")
- An 80-repeat maternal *FMR1* allele is a premutation; transmission and expansion are distinct risks. [\[1\]](#cite-1 "Reference &#91;1&#93;")
- Increased NT and familial fragile X risk demand separate, coordinated investigations. [\[7\]](#cite-7 "Reference &#91;7&#93;")
- cfDNA screens for common aneuploidies; fetal *FMR1* diagnosis requires a specifically requested assay on a diagnostic sample. [\[4\]](#cite-4 "Reference &#91;4&#93;")

The best strategy is the one that answers **both** clinical questions at a time and procedural risk the patient accepts—not simply the test with the highest aneuploidy screening performance. [\[4\]](#cite-4 "Reference &#91;4&#93;")

 Frequently Asked Questions 
----------------------------

###     Does a low-risk cfDNA result rule out fragile X syndrome in this pregnancy?             

No. Standard cfDNA aneuploidy screening does not replace targeted fetal *FMR1* repeat analysis. [\[4\]](#cite-4 "Reference &#91;4&#93;")

###     Does an 80-repeat maternal allele mean the fetus has fragile X syndrome?             

No. It identifies a maternal premutation. The fetus must inherit that allele and it must expand to a full mutation for the usual fragile X syndrome mechanism. [\[1\]](#cite-1 "Reference &#91;1&#93;")

###     Why might amniocentesis follow an FMR1 result from CVS?             

CVS can establish repeat size, but an uncertain methylation result may require confirmation using amniotic fluid cells. [\[1\]](#cite-1 "Reference &#91;1&#93;")

###     If fetal genetic testing is negative, is follow-up ultrasound still necessary?             

Yes. An increased NT warrants detailed structural assessment even when testing for the selected genetic conditions is negative. [\[7\]](#cite-7 "Reference &#91;7&#93;")

 References  (9)  
------------------

 1. 1.  [ www.ncbi.nlm.nih.gov/sites/books/NBK1384     ](https://www.ncbi.nlm.nih.gov/sites/books/NBK1384/)   [↩](#cite-ref-1-1 "Back to text")
2. 2.  [ www.isuog.org/static/20863053-3657-4896-b62e823d2d2d25f2/LISA-HUI-Kelly-2021-increased-NT-pd6024.pdf     ](https://www.isuog.org/static/20863053-3657-4896-b62e823d2d2d25f2/LISA-HUI-Kelly-2021-increased-NT-pd6024.pdf)   [↩](#cite-ref-2-1 "Back to text")
3. 3.  [ pubmed.ncbi.nlm.nih.gov/10214502     ](https://pubmed.ncbi.nlm.nih.gov/10214502/)   [↩](#cite-ref-3-1 "Back to text")
4. 4.  [ ACOG. Screening for Fetal Chromosomal Abnormalities. Practice Advisory, January 2026.     ](https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2026/01/screening-for-fetal-chromosomal-abnormalities)   [↩](#cite-ref-4-1 "Back to text")
5. 5.  [ www.acog.org/womens-health/faqs/amniocentesis     ](https://www.acog.org/womens-health/faqs/amniocentesis)   [↩](#cite-ref-5-1 "Back to text")
6. 6.  [ ACOG. Ethical Considerations for Genetic Testing and Counseling in Obstetrics and Gynecology. 2026.     ](https://www.acog.org/clinical/clinical-guidance/committee-statement/articles/2026/02/ethical-considerations-for-genetic-testing-and-counseling-in-obstetrics-and-gynecology)   [↩](#cite-ref-6-1 "Back to text")
7. 7.  [ www.acog.org/advocacy/policy-priorities/non-invasive-prenatal-testing/current-acog-guidance     ](https://www.acog.org/advocacy/policy-priorities/non-invasive-prenatal-testing/current-acog-guidance)   [↩](#cite-ref-7-1 "Back to text")
8. 8.  [ ACOG. Carrier Screening for Genetic Conditions. Committee Opinion No. 691.     ](https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/03/carrier-screening-for-genetic-conditions)
9. 9.  [ GeneReviews. FMR1 Disorders.     ](https://www.ncbi.nlm.nih.gov/books/NBK1384/)

Next step

 Build confidence in OB/GYN with focused practice 
--------------------------------------------------

 - Labor &amp; delivery + postpartum essentials
- Gynecology, screening, and common procedures
- Review weak topics and improve faster

 [     Start practicing ](https://mdster.com/user/dashboard)  [     Explore Obstetrics &amp; Gynecology ](https://mdster.com/speciality/obstetrics-gynecology)  

   [ View pricing ](https://mdster.com/pricing) [ Explore features ](https://mdster.com/features)  

 No credit card required. Full access to all features\*. No commitment. Cancel anytime.

 \*AI SOE Examiner is limited to 10 cases monthly for Advanced &amp; Bundle subscribers.

   Explore topics:  [ # Obstetrics &amp; Gynecology ](https://mdster.com/blog?tag=obstetrics-gynecology) [ # Case Discussion ](https://mdster.com/blog?tag=case-discussion) [ # Genetic Counseling ](https://mdster.com/blog?tag=genetic-counseling) [ # Fragile X Syndrome ](https://mdster.com/blog?tag=fragile-x-syndrome) [ # Prenatal Genetics ](https://mdster.com/blog?tag=prenatal-genetics) [ # Nuchal Translucency ](https://mdster.com/blog?tag=nuchal-translucency)  

  [     Back to all posts ](https://mdster.com/blog) 

 Discussion  ()  
-----------------

 Join the discussion

 [     Log in ](https://mdster.com/auth/login) or [     Sign up ](https://mdster.com/auth/register) 

No comments yet

Be the first to share your thoughts!

    ![]()     

More in Case Discussion
-----------------------

 [ See all     ](https://mdster.com/blog?category=case-discussion) 

  [###  Amniotic Fluid Embolism During Labor: Anesthesia Case Discussion 

      7 min read       Nov 21, 2026

     ](https://mdster.com/blog/amniotic-fluid-embolism-during-labor-anesthesia-case-discussion) [###  Adolescent Self-Harm: A Case of Unsafe Discharge and Repeat Injury 

      7 min read       Nov 19, 2026

     ](https://mdster.com/blog/adolescent-self-harm-a-case-of-unsafe-discharge-and-repeat-injury) [###  Severe Preeclampsia and Urgent Cesarean: An Anesthesia Case Discussion 

      7 min read       Nov 17, 2026

     ](https://mdster.com/blog/severe-preeclampsia-and-urgent-cesarean-an-anesthesia-case-discussion)  

Related Posts
-------------

  [                                ![Amniotic Fluid Embolism During Labor: Anesthesia Case Discussion](https://mdster.com/storage/blog/images/amniotic-fluid-embolism-during-labor-anesthesia-case-discussion.png)         Case Discussion 

###  Amniotic Fluid Embolism During Labor: Anesthesia Case Discussion 

 A laboring patient collapses during epidural placement. Work through the competing diagnoses, pregnancy-specific resuscitation, hemorrhage control, and ICU decisions.

     7 min read 

     0 comments 

 ](https://mdster.com/blog/amniotic-fluid-embolism-during-labor-anesthesia-case-discussion) [       Case Discussion 

###  Adolescent Self-Harm: A Case of Unsafe Discharge and Repeat Injury 

 A teenager re-presents with serious self-harm after discharge without specialist assessment. Examine admission decisions, safeguarding, epilepsy and safer care pathways.

     7 min read 

     0 comments 

 ](https://mdster.com/blog/adolescent-self-harm-a-case-of-unsafe-discharge-and-repeat-injury) [                                ![Reference Ranges and Pregnancy-Adjusted Labs: Avoiding Clinical Traps](https://mdster.com/storage/blog/images/reference-ranges-and-pregnancy-adjusted-labs-avoiding-clinical-traps.png)         Medical Education 

###  Reference Ranges and Pregnancy-Adjusted Labs: Avoiding Clinical Traps 

 A lab result can look reassuring—or alarming—for the wrong reason in pregnancy. Learn which reference ranges change, which thresholds matter, and when symptoms override the number.

     2 min read 

     0 comments 

 ](https://mdster.com/blog/reference-ranges-and-pregnancy-adjusted-labs-avoiding-clinical-traps) [                                ![Severe Preeclampsia and Urgent Cesarean: An Anesthesia Case Discussion](https://mdster.com/storage/blog/images/severe-preeclampsia-and-urgent-cesarean-an-anesthesia-case-discussion.png)         Case Discussion 

###  Severe Preeclampsia and Urgent Cesarean: An Anesthesia Case Discussion 

 A case-based approach to urgent cesarean anesthesia in severe preeclampsia, covering HELLP evaluation, neuraxial decisions, airway strategy, pulmonary edema, and magnesium toxicity.

     7 min read 

     0 comments 

 ](https://mdster.com/blog/severe-preeclampsia-and-urgent-cesarean-an-anesthesia-case-discussion) [                                ![Gambling Disorder and Bipolar Symptoms: A Psychiatry Case Discussion](https://mdster.com/storage/blog/images/gambling-disorder-and-bipolar-symptoms-a-psychiatry-case-discussion.png)         Case Discussion 

###  Gambling Disorder and Bipolar Symptoms: A Psychiatry Case Discussion 

 A case-based approach to gambling disorder complicated by possible mania, suicide risk, family safeguarding, medication selection, and relapse prevention.

     7 min read 

     0 comments 

 ](https://mdster.com/blog/gambling-disorder-and-bipolar-symptoms-a-psychiatry-case-discussion) [                                ![PCOS and Metabolic Syndrome: Advanced Management Before Pregnancy](https://mdster.com/storage/blog/images/pcos-and-metabolic-syndrome-advanced-management-before-pregnancy.png)         Medical Education 

###  PCOS and Metabolic Syndrome: Advanced Management Before Pregnancy 

 A patient with PCOS needs more than ovulation induction. Learn how to assess metabolic risk, sequence fertility treatment, and plan pregnancy surveillance.

     6 min read 

     0 comments 

 ](https://mdster.com/blog/pcos-and-metabolic-syndrome-advanced-management-before-pregnancy)  

  [  MDster home ](/ "MDster home")

 Master your medical exams with evidence-based learning.

 [    Download on the App Store 

 ](https://apps.apple.com/app/id6759168258) [       GET IT ON Google Play 

 ](https://play.google.com/store/apps/details?id=com.mdster.app) 

Platform

- [Home](https://mdster.com)
- [Features](https://mdster.com/features)
- [Pricing](https://mdster.com/pricing)
- [About](https://mdster.com/about)

Resources

- [Blog](https://mdster.com/blog)
- [Curriculum](https://mdster.com/curriculum)
- [Claude &amp; ChatGPT](https://mdster.com/ai-assistants)
- [Dashboard](https://mdster.com/user/dashboard)

Support

- [Contact](https://mdster.com/contact)
- [Legal &amp; Policies](https://mdster.com/legal)
- [Medical Reviewers](https://mdster.com/medical-reviewers)

 © 2026 MDster

  [Terms](https://mdster.com/terms) [Privacy](https://mdster.com/privacy) [Editorial](https://mdster.com/editorial-policy)  [    ](https://apps.apple.com/app/id6759168258) [    ](https://play.google.com/store/apps/details?id=com.mdster.app) 

     reCAPTCHA 

 Protected by reCAPTCHA.

 Google [Privacy Policy](https://policies.google.com/privacy) and [Terms of Service](https://policies.google.com/terms) apply.

Cookie Consent
--------------

 We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. [ Terms of Use ](https://mdster.com/terms) &amp; [ Privacy Policy ](https://mdster.com/privacy)

  Accept
